China's Biopharmaceutics towards the world

Source: U.S - China Pharmaceutical source June 16, 2017 [news event]: Today Damian garde, a reporter from stat, wrote an article saying that China's biopharmaceuticals are becoming a strong force in the world's new drugs, and will discover new drugs for the world in the future The main reason for this view is that the car-t data of Nanjing legend biology has made many people look at Chinese biomedicine differently It also points out that the thousand talents plan attracts a large number of overseas returnees, the remarkable progress of local talent training, and the integration of drug regulatory reform with the world, but at the same time, it also points out that China's capital market is not conducive to unprofitable biopharmaceutical companies Finally, the article said that the United States may not always be at the top of the new drug food chain, and it will be a challenge sooner or later [drug source analysis]: new drugs are considered to be one of the most complex intellectual activities, so it is worth celebrating that China's new drug research and development is recognized by the world Car-t is also a high-tech project in biopharmaceutics It is not easy for legendary biology and Bluebird to complete the first phase of car-t clinical data for BCMA, a new target In my limited memory, this is the closest China's new drug research and development is to the forefront of the world This achievement is relatively similar to that of Chinese new drugs It is a encouragement for other enterprises that the women's volleyball team won the world championship when China's overall sports fell behind It is important to be close to the world level in some areas first, because it is a heavy psychological burden to not know how much behind I think China already has the global competition to participate in new drug research and development in many aspects In addition to the factors mentioned in stat, the accumulation of cro over the years has cultivated technical talents for each stage of new drugs, and the R & D center established by multinational enterprises in China has also formed a talent flow biosphere The internationalization of information makes the world share new target data equally, and the frequent high-end academic conferences held in China also speed up the spread of new ideas Although the stock market is disadvantageous to early R & D enterprises, a large number of private capital does not contradict new drugs It is also an advantage that the hard work of the younger generation of Chinese pharmaceutical industry is rare in the world Of course, these theoretical conditions do not necessarily translate into successful R & D projects South Korea and Israel may have the same conditions, but there are still few people in the world pharmaceutical industry Japan, which started earlier, is now hard to compete with Europe and the United States, so there are still some details to be improved Experience and overall execution are short boards New drugs are a secret industry, and many information will never be disclosed, so it is difficult for outsiders to learn some of the experience passed down from generation to generation by old R & D enterprises Although all the scientists who read CNS can see the new target, it still needs some industry experience and internal evaluation system to judge its importance, reliability and priority It is not possible to build a large and high-quality compound library in a short time To say that China's biopharmaceutical industry is going global means that some projects are expected to be listed in Europe and the United States, and it will take time for such a giant enterprise as MSD to appear In this way, enterprises not only need comprehensive R & D facilities, but also need to be very solid in the operation, promotion, registration, policy lobbying and other aspects of the main markets in Europe and the United States Even old brand pharmaceutical factories like Takeda still have a gap with European and American enterprises in these aspects Not to mention that there are still many shortcomings in China Even in Europe and the United States, where everything is ready, there are large enterprises such as Wyeth, puqiang and Schering that are constantly evaporating from the world In the past, one or two big drugs can turn you into a big Mac Now the competition is fierce Within a few years, you will be demoted from group A to group B or even be merged As for replacing the United States as the leader, we have to take a long-term view This is the same as saying that Brazil is not always the strongest team in the world Although there is no theoretical error, it may only be theoretical at present New drugs are like football You can make 80-90% of the best teams, but you can still win and lose Even compared with the world's top teams, the national football team may not lose 1:5 (compared with the youth team of Thailand, of course) Similarly, even if your R & D success rate reaches 50% of MSD, you may lose money It has been a great progress to participate in the competition of new drugs in the world After all, there are only a few countries that have the ability to discover new drugs.